Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin

Gene Therapy

Volumn 12, Issue 14, 2005, Pages 1099-1108

  Li, S ^a   Kimura, E ^a   Fall, B M ^a   Reyes, M ^a   Angello, J C ^a   Welikson, R ^a   Hauschka, S D ^a   Chamberlain, J S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CK6; DMD; Gene transfer; mdx lentiviral vector; Mini dystrophin; Myogenic progenitors

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; CREATINE KINASE; CREATINE KINASE 6; DYSTROPHIN; EVANS BLUE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA MODIFICATION; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIPOTENT STEM CELL; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE TRANSPLANTATION; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SKELETAL MUSCLE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DYSTROPHIN; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; LENTIVIRUS; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; STEM CELLS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 22744459591     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302505     Document Type: Article

References (50)

1. Emery AEH (ed). The Muscular Dystrophies. Oxford University Press Inc.: New York, Oxford, 2001.
2. Gregorevic P, Chamberlain JS. Gene therapy for muscular dystrophy - a review of promising progress. Expert Opin Biol Ther 2003; 3: 803-814.
3. Cox GA et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993; 364: 725-729.
4. Harper SQ et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8: 253-261.
5. DelloRusso C et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA 2002; 99: 12979-12984.
6. Gregorevic P et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828-834.
7. Vincent-Lacaze N et al. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999; 73: 1949-1955.
8. Schnepp BC et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003; 77: 3495-3504.
9. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
10. Snyder RO et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891-1900.
11. Harui A, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999; 73: 6141-6146.
12. Kafri T et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-317.
13. Seppen J, Barry SC, Harder B, Osborne WR. Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 2001; 98: 594-596.
14. MacKenzie TC et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002; 6: 349-358.
15. Kobinger GP et al. Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum Gene Ther 2003; 14: 1441-1449.
16. Bischoff R. The satellite cell and muscle regeneration. In: Andrew G, Engel CF-A (eds). Myology. McGraw-Hill Inc., 1994: pp 97-118.
17. Gussoni E et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401: 390-394.
18. Jankowski RJ, Haluszczak C, Trucco M, Huard J. Flow cytometric characterization of myogenic cell populations obtained via the preplate technique: potential for rapid isolation of muscle-derived stem cells. Hum Gene Ther 2001; 12: 619-628.
19. Jiang Y et al. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 2002; 30: 896-904.
20. Bujold M et al. Autotransplantation in mdx mice of mdx myoblasts genetically corrected by an HSV-1 amplicon vector. Cell Transplant 2002; 11: 759-767.
21. Floyd Jr SS et al. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Therapy 1998; 5: 19-30.
22. Moisset PA, Gagnon Y, Karpati G, Tremblay JP. Expression of human dystrophin following the transplantation of genetically modified mdx myoblasts. Gene Therapy 1998; 5: 1340-1346.
23. Hartigan-O'Connor D et al. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001; 4: 525-533.
24. Cordier L et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12: 205-215.
25. Hauser MA et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2000; 2: 16-25.
26. Neville C et al. Skeletal muscle cultures. Methods Cell Biol 1997; 52: 85-116.
27. Clegg CH, Linkhart TA, Olwin BB, Hauschka SD. Growth factor control of skeletal muscle differentiation: commitment to terminal differentiation occurs in G1 phase and is repressed by fibroblast growth factor. J Cell Biol 1987; 105: 949-956.
28. Chamberlain JS, Jaynes JB, Hauschka SD. Regulation of creatine kinase induction in differentiating mouse myoblasts. Mol Cell Biol 1985; 5: 484-492.
29. Jaynes JB et al. Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts. Mol Cell Biol 1986; 6: 2855-2864.
30. Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 1998; 9: 457-463.
31. Nguyen TH et al. Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther 2002; 6: 199-209.
32. Bonci D et al. 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Therapy 2003; 10: 630-636.
33. Naldini L et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
34. Chen W et al. Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice. Stem Cells 2000; 18: 352-359.
35. Montanaro F et al. Skeletal muscle engraftment potential of adult mouse skin side population cells. Proc Natl Acad Sci USA 2003; 100: 9336-9341.
36. Bachrach E et al. Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc Natl Acad Sci USA 2004; 101: 3581-3586.
37. Acsadi G et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Genet 1994; 3: 579-584.
38. Nalbantoglu J, Pari G, Karpati G, Holland PC. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 1999; 10: 1009-1019.
39. Bilbao R et al. Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors. Gene Therapy 2003; 10: 1821-1829.
40. Guibinga GH, Miyanohara A, Esko JD, Friedmann T. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 2002; 5: 538-546.
41. Cao B, Mytinger JR, Huard J. Adenovirus mediated gene transfer to skeletal muscle. Microsc Res Technol 2002; 58: 45-51.
42. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM. Principles of Virology, Molecular Biology, Pathogenesis, and Control. ASM press: Washington DC, 2000.
43. Scherr M et al. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Therapy 2002; 9: 1708-1714.
44. Follenzi A, Naldini L. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol 2002; 346: 454-465.
45. Hartigan-O'Connor D, Barjot C, Salvatori G, Chamberlain JS. Generation and growth of gutted adenoviral vectors. Methods Enzymol 2002; 346: 224-246.
46. Potter M et al. Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors. Methods Enzymol 2002; 346: 413-430.
47. Blankinship MJ et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 2004; 10: 671-678.
48. Barry SC et al. Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 2001; 12: 1103-1108.
49. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1994; 1: 136-138.
50. Miller JB, Crow MT, Stockdale FE. Slow and fast myosin heavy chain content defines three types of myotubes in early muscle cell cultures. J Cell Biol 1985; 101: 1643-1650.